Securian Asset Management Inc. Decreases Holdings in Boston Scientific Corporation $BSX

Securian Asset Management Inc. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 71,560 shares of the medical equipment provider’s stock after selling 5,749 shares during the quarter. Securian Asset Management Inc.’s holdings in Boston Scientific were worth $6,986,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Steph & Co. acquired a new position in Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $26,000. Sound Income Strategies LLC boosted its stake in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 93,095 shares of company stock valued at $9,305,450. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Barclays increased their target price on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $124.95.

Boston Scientific Trading Up 2.3%

NYSE:BSX opened at $97.70 on Wednesday. The company has a market cap of $144.84 billion, a PE ratio of 52.25, a P/E/G ratio of 1.69 and a beta of 0.67. The business’s 50 day moving average is $97.72 and its two-hundred day moving average is $100.85. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the business earned $0.63 EPS. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.